Milestones

1.    Several competitive public funded projects were initiated; 1) ISCIII, a project (PI21/00828) and Red de Investigación Cooperativa en Salud (RD21/0002/0053), 2) MICINN, a public-private collaboration project (CPP2021-008512); 3) CAM-EU, to finance a consortium studying the response to COVID vaccines in patients with Multiple Sclerosis (REACT-EU INMUNOVACTER-CM).

2.    Publication of a pioneering research paper supporting the importance of highly effective early treatment in the prevention of long-term disability in patients with Multiple Sclerosis (MS). It describes a serum biomarker (sNfL) that identifies MS patients at high risk of medium-term disability progression and has identified treatments capable of halting the aggressive course in these patients. The prestigious scientific journal JAMA Neurology has published the results of this research which, in the opinion of the research team "opens new avenues for the personalization of treatment in Multiple Sclerosis".doi: 10.1001/jamaneurol.2023.0010.  

3.    Implementation of research results in clinical practice; 1) Description of an algorithm for effective and safe retreatment of MS patients with anti-CD20 (doi: 10.1016/j.msard.2022.104218). 2) serum biomarker to identify patients with inflammatory and non-inflammatory primary progressive multiple sclerosis (PPMS) (doi: 10.3389/fimmu.2022.842354).

Success in competitive calls for research personnel: an ISCIII Rio Hortega Contract (CM22/00163) for the study of biomarkers in Multiple Sclerosis and a PADI contract for the study of immunomonitoring of CAR-T therapies in the treatment of hematological malignancies.

5.    Intramural funding of IRYCIS for the implementation of an eHealth strategy in the management of patients with Multiple Sclerosis.